Pharmaceutical Trials

A Track Record Across Therapeutic Areas

On 1 October 2001, EB Medical Research signed its first study contract for an obesity study. Since then, we have built more than two decades of experience conducting Phase 1 through Phase 3 pharmaceutical trials for leading global pharmaceutical sponsors, spanning 80 clinical studies with over 900 subjects over the last 10 years alone. Our core team combines deep clinical and operational expertise: our Principal Investigator brings 25 years of clinical trial experience, and the rest of our core team each bring 15+ years.

Our Experience

We conduct Phase 2 and 3 studies across virtually any therapeutic area, from metabolic and cardiovascular to allergy, respiratory and beyond. If your study doesn’t require inpatient care or hospital-grade infrastructure, we’re the right fit.

Indications

Our most frequent indications include diabetes, overweight and obesity, cardiovascular disease, chronic kidney disease, respiratory disease, women’s health and pain.

GLP-1 Receptor agonists
EBMR has been involved in GLP-1 receptor agonist research since the earliest stages of the class’s development, progressing from first-generation single-agonist products to today’s compounds that combine complementary mechanisms of action, as well as novel oral formulations. We currently run 5 studies in this area, with various sponsors.

Facility Highlights for Pharmaceutical Studies

Our Almere site is equipped for the operational demands of pharmaceutical trials:

  • Two -80°C ultra-low temperature freezers for long-term sample storage
  • On-site sample processing: centrifuge, pipetting, aliquoting
  • 5 dedicated phlebotomy chairs for extended PK visits up to 8 hours
  • Dedicated clinical research rooms for supervised dosing and monitoring visits
  • On-site ECG and vital signs monitoring equipment
  • All site staff are trained and certified to ICH GCP E6(R3)
  • On-site investigational medicinal product pharmacy,
    a separate unit in the building, operated by licensed pharmacist (Pharmaserv)
  • Note: All equipment is calibrated annually

Subject Recruitment,
a Key Strength

For pharmaceutical studies, timely and reliable recruitment is often the deciding factor for site selection. At EB Medical Research, this is one of our strongest capabilities.

Our database:

  • Approximately 4,500 registered volunteers across the greater Amsterdam–Almere–Gooi region
  • Broad age range; targeted selection by age, health status and availability
  • Proven reach beyond the immediate region, repeat participants from areas at more than 150 km distance

Our approach:

Before recruitment starts, we assess the expected recruitment strategy based on the study’s inclusion and exclusion criteria, subject burden, compensation level and recruitment period. This assessment informs our advice on whether additional support, such as an external recruitment agency, is needed to meet enrollment targets within the required timeline.

We are continuously working to optimize the response to our recruitment calls. A single, concise message with a direct call-to-action and an integrated option to schedule an information call consistently delivers high response rates. For specific age groups or profiles, we activate participant referral, which has reliably filled slots in every study to date.

 

Reference Project

Cardiometabolic Outcomes Study

Global pharmaceutical company | Indication: overweight/obesity with cardiovascular and renal comorbidity | Investigational product: a triple GIP/GLP-1/glucagon receptor agonist | 17 subjects enrolled

An ongoing outcomes study evaluating a triple GIP/GLP-1/glucagon receptor agonist in adults with overweight or obesity and cardiovascular or renal comorbidity. The study is now in year 2 of an expected 5-year duration.

Operational highlights:

  • Feasibility turned around the same day it was received
  • Recruitment from first screening to last randomization: approximately 4 months
  • 25 candidates screened, 17 randomized — exceeding the original enrollment target of 15
  • Recruited from EBMR’s own database, supported by a modest advertising budget (social media)
  • 100% subject retention after 2 years 

Why Work with EB Medical Research?

  • Highly experienced
    Extensive experience enables effective communication, short start-up times, and a low likelihood of protocol deviations. 
  • Short lines in decision-making, contracting and start-up
    Direct access to the PI and site director for protocol or contract decisions, without layers of internal approval.
  • Dedication and focus on studies
    Clinical trials are our sole business, not a side activity alongside routine patient care. We are driven to achieve the targets set for each study. As a result, sponsors have been returning to have EBMR conduct their new studies for 25 years.
  • High Sponsor Satisfaction
    Sponsors consistently report high satisfaction with how their studies are executed, from feasibility through close-out. That track record is reflected in the number of sponsors who return to us for follow-up studies.
  • Patient orientation drives high retention rates
    As a non-treating site, our candidate research participants are of fundamental importance to us. We treat our participants with great care and attention, which is reflected in high (measured) patient satisfaction, high retention rates and returning participants.
  • Large candidate database
    Over time, we have built a database of 4,500 research-interested candidates, collected with their consent. Sponsors sometimes assume a hospital-based site is required to reach their target population, particularly for chronic or comorbid conditions. Our database and outreach reach that same population directly, as demonstrated in the reference project above.

Let's discuss your study

If you are looking for a reliable site to add to your network, we are happy to discuss feasibility.

We respond within 16 business hours.

Request a Feasibility